Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Ceryvyn TherapeuticsCKDXF 3-Year EBITDA Growth Rate is 27.20% as of Jun. 2025. The stock has 3 warning signs investors should review. Among 1,135 Biotechnology companies, Ceryvyn Therapeutics ranks better than 63.17% on this metric.
During the past 3 years, the average EBITDA Per Share Growth Rate was 27.20% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was -19.50% per year.
During the past 10 years, the average EBITDA Per Share Growth Rate was -22.50% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of Ceryvyn Therapeutics was 46.90% per year. The lowest was -157.10% per year. And the median was -12.05% per year.
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Ceryvyn Therapeutics 3-Year EBITDA Growth Rate Related Terms
CKDXF vs VRTX, REGN, RVMD: 3-Year EBITDA Growth Rate Comparison
For the Biotechnology subindustry, Ceryvyn Therapeutics's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ceryvyn Therapeutics 3-Year EBITDA Growth Rate vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Ceryvyn Therapeutics's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Ceryvyn Therapeutics's 3-Year EBITDA Growth Rate falls into.
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 27.20% mean?
Ceryvyn Therapeutics (CKDXF) has a 3-Year EBITDA Growth Rate of 27.20% as of Jun. 2025. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Ceryvyn Therapeutics and its competitors. According to the industry distribution chart, Ceryvyn Therapeutics ranks #418 out of 1135 companies in the Biotechnology industry, placing it in the top 36.8%.
Is Ceryvyn Therapeutics' 3-Year EBITDA Growth Rate too high?
Ceryvyn Therapeutics' current 3-Year EBITDA Growth Rate is 27.20%. The Biotechnology industry median 3-Year EBITDA Growth Rate is 14.80. Ceryvyn Therapeutics' value of 27.20% is 83.8% above this industry median. Based on the distribution chart, Ceryvyn Therapeutics ranks #418 out of 1135 companies in the Biotechnology industry, which is above the industry midpoint.
How does Ceryvyn Therapeutics' 3-Year EBITDA Growth Rate compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Ceryvyn Therapeutics ranks #418 out of 1135 companies for 3-Year EBITDA Growth Rate. This puts Ceryvyn Therapeutics in the upper half of its industry. The industry median 3-Year EBITDA Growth Rate is 14.80. Ceryvyn Therapeutics' value of 27.20% is 83.8% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Biotechnology company?
The median 3-Year EBITDA Growth Rate among Biotechnology companies is 14.80, based on 1,135 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Ceryvyn Therapeutics's current 3-Year EBITDA Growth Rate of 27.20% is 83.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Ceryvyn Therapeutics and its competitors. For the Biotechnology industry, the median 3-Year EBITDA Growth Rate is 14.80 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Ceryvyn Therapeutics's current 3-Year EBITDA Growth Rate is 27.20%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ceryvyn Therapeutics stock overvalued right now?
Ceryvyn Therapeutics (CKDXF) has a current 3-Year EBITDA Growth Rate of 27.20%. The current 3-Year EBITDA Growth Rate is 27.20% and 83.8% above the Biotechnology industry median of 14.80. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Ceryvyn Therapeutics (CKDXF), the current 3-Year EBITDA Growth Rate is 27.20% as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Opthea Ltd is engaged in researching and developing novel therapeutic products that target Vascular Endothelial Growth Factors (VEGF) C, D, and R3. The Group operates in one industry and two geographical areas, namely biotechnology and healthcare, with operations in Australia and the United States. The company focuses on developing biological therapeutics for eye diseases and is currently developing a novel biologic therapy, OPT-302, for the treatment of eye conditions. Its products are based on an intellectual property portfolio covering VEGF-C, VEGF-D, and VEGF Receptor-3 targets, aimed at treating diseases associated with blood and lymphatic vessel growth and vascular leakage.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CKDXF has been successfully added to your 
